ImmunoClin Corp. (IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals.
In its release, the Company said that it is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders. As of August 1, ImmunoClin Corp. completed the strategic relocation of its corporate headquarters to Washington, D.C., a key center of North American healthcare and biotechnology industries and related governmental agencies. In addition, the Company's chief operating officer, general counsel, and director, Chad S. Johnson, Esq., who will oversee the principal corporate office, is a decades-long D.C. resident.
"We are excited to move ImmunoClin's head office to Washington, D.C. The location is attractive for obvious regulatory and business reasons, as we continue to progress our strategic growth plan. Further, under the oversight of officer and director, Chad Johnson, the Washington office will work seamlessly with our established European headquarters in London, United Kingdom and laboratories in central Paris, France," said Dr. Dorothy Bray, Director, President and CEO of ImmunoClin Corp.
"Washington, D.C. is a great location for the Company's principal office. ImmunoClin will join the ranks of the expansive tech and healthcare presence in the D.C. area and be positioned to take advantage of the proximity to and interaction with the federal government, including departments and agencies such as HHS, FDA, NIH, USPHS, and USPTO -- not to mention the impressive public and private educational and research institutions located in greater D.C.," said Chad S. Johnson, Esq., Director, COO and General Counsel. "I am honored to spearhead the efforts of IMCL from our new D.C. office in conjunction with our international board of directors and scientific advisory board."
More Information and Complete Details:
((Comments on this story may be sent to firstname.lastname@example.org))